Pharmaceuticals, Biotechnology and Life Sciences
Ignis Therapeutics and STADA’s Britannia Pharmaceuticals Ltd. affiliate have jointly announced that two companies have signed an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson’s disease in mainland China, Hong Kong and Macau.
Stada said Thursday it increases its indirect shareholding in the Vietnamese pharmaceutical company Pymepharco JSC to 72 percent, with a…
Stada has announced the new name to succeed the current CEO Claudio Albrecht in September this year.
STADA Arzneimittel AG is advancing the internationalization of its OTC brand business. On January 12, 2018, the company reached an…
Frank Staud assumed the role of Executive Vice President Corporate Communications, Branding and Sponsoring on October 1. The 48-year old…
Stada’s Executive Board presented sound figures for financial year 2016 and a positive outlook for business development in 2017. Board’s…
Nidda Healthcare Holding AG, the acquiring company of Bain Capital und Cinven, announced Friday that the minimum acceptance threshold set by the bidder at 63 percent in the offer document published on July 19, 2017 was reached.
STADA Arzneimittel AG has appointed Engelbert Coster Tjeenk Willink as Chief Executive Officer with immediate effect.
Stada Arzneimittel has reported adjusted net income of €53.3 million for the first quarter of 2017 which is 33% increase compared to last years net income of €40.1 million.
STADA Arzneimittel AG has appointed Dr. Ralph Grobecker as Managing Director at STADA GmbH.